These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 874092)

  • 1. Dysfibrinogenemia associated with liver disease.
    Palascak JE; Martinez J
    J Clin Invest; 1977 Jul; 60(1):89-95. PubMed ID: 874092
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Abnormal sialic acid content of the dysfibrinogenemia associated with liver disease.
    Martinez J; Palascak JE; Kwasniak D
    J Clin Invest; 1978 Feb; 61(2):535-8. PubMed ID: 621288
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fibrinogen Cleveland II. An abnormal fibrinogen with defective release of fibrinopeptide A.
    Crum ED; Shainoff JR; Graham RC; Ratnoff OD
    J Clin Invest; 1974 May; 53(5):1308-19. PubMed ID: 4856883
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dysfibrinogenemia and lupus anticoagulant in a patient with recurrent thrombosis.
    Al-Mondhiry H; Galanakis D
    J Lab Clin Med; 1987 Dec; 110(6):726-33. PubMed ID: 3119749
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dysfibrinogenaemia characterized by abnormal fibrin monomer polymerization and normal fibrinopeptide A release.
    Lane DA; Cuddigan B; VanRoss M; Kakkar VV
    Br J Haematol; 1980 Mar; 44(3):483-94. PubMed ID: 6769460
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fibrinogen Sevilla, a congenital dysfibrinogenemia characterized by an abnormal monomer aggregation and a defective plasmin lysis.
    Fernández FJ; Noguerol P; Sosa R; Cuesta B; Páramo JA; Rocha E
    Clin Chim Acta; 1989 Feb; 179(3):239-50. PubMed ID: 2713997
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acquired dysfibrinogenaemia in acute and chronic liver disease.
    Lane DA; Scully MF; Thomas DP; Kakkar VV; Woolf IL; Williams R
    Br J Haematol; 1977 Feb; 35(2):301-8. PubMed ID: 870000
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel mutation in the fibrinogen Aα chain (Gly13Arg, fibrinogen Nanning) causes congenital dysfibrinogenemia associated with defective peptide A release.
    Yan J; Luo M; Cheng P; Liao L; Deng X; Deng D; Lin F
    Int J Hematol; 2017 Apr; 105(4):506-514. PubMed ID: 27933517
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fibrinogen Bethesda: a congenital dysfibrinogenemia with delayed fibrinopeptide release.
    Gralnick HR; Givelber HM; Shainoff JR; Finlayson JS
    J Clin Invest; 1971 Sep; 50(9):1819-30. PubMed ID: 5564389
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fibrinogen Magdeburg I: a novel variant of human fibrinogen with an amino acid exchange in the fibrinopeptide A (Aalpha 9, Leu-->Pro).
    Meyer M; Kutscher G; Stürzebecher J; Riesener G; Lutze G
    Thromb Res; 2003 Jan; 109(2-3):145-51. PubMed ID: 12706644
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acquired dysfibrinogenemia in a hemophiliac with hepatoma: resolution of fibrinogen dysfunction following chemotherapy.
    Ballard JO; Kelly GA; Kukrika MD; Sanders JC; Eyster ME
    Cancer; 1981 Aug; 48(3):686-90. PubMed ID: 6265056
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fibrinogen Philadelphia. A hereditary hypodysfibrinogenemia characterized by fibrinogen hypercatabolism.
    Martinez J; Holburn RR; Shapiro SS; Erslev AJ
    J Clin Invest; 1974 Feb; 53(2):600-11. PubMed ID: 11344575
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fibrinogen Aarhus--a new case of dysfibrinogenemia.
    Hessel B; Stenbjerg S; Dyr J; Kudryk B; Therkildsen L; Blombäck B
    Thromb Res; 1986 Apr; 42(1):21-37. PubMed ID: 2939591
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fibrinogen Alès: a homozygous case of dysfibrinogenemia (gamma-Asp(330)-->Val) characterized by a defective fibrin polymerization site "a".
    Lounes KC; Soria C; Mirshahi SS; Desvignes P; Mirshahi M; Bertrand O; Bonnet P; Koopman J; Soria J
    Blood; 2000 Nov; 96(10):3473-9. PubMed ID: 11071644
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fibrinogen Houston: a dysfibrinogen exhibiting defective fibrin monomer aggregation and alpha-chain cross-linkages.
    Weinger RS; Rudy C; Moake JL; Conlon CL; Cimo PL
    Am J Hematol; 1980; 9(3):237-48. PubMed ID: 6165239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Acquired dysfibrinogenemia in a child in the course of a liver disease].
    Maak B; Meyer M; Dietze H
    Monatsschr Kinderheilkd; 1990 Aug; 138(8):446-50. PubMed ID: 2215508
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fibrinopeptide A release is necessary for effective B:b interactions in polymerisation of variant fibrinogens with impaired A:a interactions.
    Soya K; Terasawa F; Okumura N
    Thromb Haemost; 2013 Feb; 109(2):221-8. PubMed ID: 23238100
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An abnormal inherited fibrinogen (fibrinogen Genova) with delayed fibrin aggregation.
    Hassan HJ; Orlando M; Tonini GP; Casalbore P; Sarti A; Boeri E; Giacchino R; Tentori L; Mori PG
    Scand J Haematol; 1982 Oct; 29(4):287-94. PubMed ID: 7178834
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fibrinogen Bondy: a new case of dysfibrinogenemia. Isolation of the abnormal fibrinogen molecules.
    Jandrot-Perrus M; Aurousseau MH; Rabiet MJ; Josso F
    Thromb Res; 1982 Sep; 27(6):659-70. PubMed ID: 6217586
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fibrinogen and dysfibrinogenemia.
    Morse EE
    Ann Clin Lab Sci; 1980; 10(4):351-5. PubMed ID: 7447388
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.